Abstract
Introduction: The comparative effectiveness of anti-IL5/5R versus anti-IgE among severe asthma patients is unknown
Aim: To assess clinical responses of initiating anti-IL5/5R versus anti-IgE among patients eligible for both.
Methods: Patients eligible for both anti-IL5/5R and anti-IgE who started either modality recruited between Jan 2014 and Jan 2021 to the International Severe Asthma Registry (ISAR) were included. Eligibility for both biologics was ascertained by frequently used criteria e.g., baseline biomarkers (BEC, FeNO, and serum IgE), allergen tests, and exacerbations. Post-therapy exacerbation rates were compared after being matched 1:1 by age, pre-therapy exacerbations, gender, and long-term oral corticosteroid (LTOCS) use. A Poisson regression model was used, adjusting for matching and any residual confounding.
Results: Among 10,666 ISAR patients from 19 countries, 760 anti-IL5/5R patients and 842 anti-IgE patients were eligible for both modalities and started therapy from 2014. 390 patients from each group were matched by baseline characteristics. Both groups had less exacerbations post-therapy (Figure). Anti-IL5/5R patients had a lower adjusted rate of post-therapy exacerbations (IRR:0.75, 95% CI: 0.68-0.84).
Conclusion: Among patients eligible for both therapies, anti-IL5/5R patients were less likely to report posttherapy exacerbations as compared to Anti-IgE patients.
Aim: To assess clinical responses of initiating anti-IL5/5R versus anti-IgE among patients eligible for both.
Methods: Patients eligible for both anti-IL5/5R and anti-IgE who started either modality recruited between Jan 2014 and Jan 2021 to the International Severe Asthma Registry (ISAR) were included. Eligibility for both biologics was ascertained by frequently used criteria e.g., baseline biomarkers (BEC, FeNO, and serum IgE), allergen tests, and exacerbations. Post-therapy exacerbation rates were compared after being matched 1:1 by age, pre-therapy exacerbations, gender, and long-term oral corticosteroid (LTOCS) use. A Poisson regression model was used, adjusting for matching and any residual confounding.
Results: Among 10,666 ISAR patients from 19 countries, 760 anti-IL5/5R patients and 842 anti-IgE patients were eligible for both modalities and started therapy from 2014. 390 patients from each group were matched by baseline characteristics. Both groups had less exacerbations post-therapy (Figure). Anti-IL5/5R patients had a lower adjusted rate of post-therapy exacerbations (IRR:0.75, 95% CI: 0.68-0.84).
Conclusion: Among patients eligible for both therapies, anti-IL5/5R patients were less likely to report posttherapy exacerbations as compared to Anti-IgE patients.
| Original language | English |
|---|---|
| Article number | PA1113 |
| Number of pages | 2 |
| Journal | European Respiratory Journal |
| Volume | 58 |
| Issue number | 65 |
| Early online date | 5 Sept 2021 |
| DOIs | |
| Publication status | Published - 5 Sept 2021 |
| Event | ERS International Congress 2021 - Virtual event Duration: 5 Sept 2021 → 8 Sept 2021 https://www.ersnet.org/congress-and-events/congress/ |
Keywords
- Asthma
- Management
- Severe asthma
- Treatments